transthyretin amyloidosis cardiomyopathy

Alnylam gives up on Onpattro’s US expansion after FDA rejects its rare heart disease indication

Despite receiving an endorsement from an advisory committee, the FDA has reached a different conclusion regarding the benefit-risk profile of ...